IP Verse

Astellas Pharma patent opposition analysis

CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Latest patents of Astellas Pharma opposed by its competitors

Explore Astellas Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 28, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3791896
Jan 10, 2024Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer3
EP3318259
Jan 11, 2023Stable Pharmaceutical Composition For Oral Administration2
EP3725810
Jul 6, 2022Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer2
EP3725778
Aug 18, 2021Formulations Of Enzalutamide11
EP2345410
Dec 30, 2020Controlled Release Pharmaceutical Composition6
EP3254695
Sep 9, 2020Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer1
EP2824181
Nov 14, 2018Novel Fgfr3 Fusion Product2
EP2554168
Jan 24, 2018Controlled Release Pharmaceutical Composition4

Top competitors of Astellas Pharma

Top competitors of Astellas Pharma based on patent oppositions.